Bharat Biotech Corporate Profile and Product Pipeline

www.bharatbiotech.com
Corporate Profile 2014

Fast Facts
Issues
Products
R&D Pipeline
Projects
Recognition
Executive Summary

Fast Facts

Fast Facts Issues Products R&D Pipeline Projects Recognition
Established : 1996
Promoters : Dr. Krishna & Ms. Suchitra Ella
Business Line : Vaccines and Bio-therapeutics
First Project : Hepatitis B Vaccine - US $ 3.5 Mn
Investment : Over US $ 150 Mn till date
Facility : One of the largest facilities in Asia
Personnel : 700 resources including scientists
Accreditations : Korean FDA, ANVISA, other Countries
Innovation : 50 Global patents
Vision
Mission
To offer affordable, safe
and effective healthcare
solutions to combat mankind's
most dreaded illnesses, and to
thus eradicate or at least control
their occurrence in the years to
come.
Developing next-generation
remedies through Genetic
Engineering Technologies so as to
create a healthier world.
Mission 7 Billion

Products R&D Pipeline Projects Recognition
Emerging Country Challenges
Lack of clarity on disease burden, public health focus & policies
NEGLECTEDAPPROACH
NEGLECTEDDISEASES
1 TYPHOID
2 HEPATITIS
3 ROTA
4 SCHISTOSOMIASIS
5 E. COLI
6 CHOLERA
7 OTHER DIARRHEA
1 JE
2 DENGUE
3 CHIKUNGUNYA
4 MALARIA
5 TRYPANOSOMA
6 LEISHMANIA
7 FILARIA
POLITICAL
COMMITTMENT
SCIENTIFIC
COMMITTMENT
Fast Facts Issues

Thinking Future
Today’s neglected diseases - Tomorrow’s global diseases
1 PLAGUE
2 HIV
3 INFLUENZA
4 MALARIA
1 DENGUE
2 CHIKUNGUNYA
3 TRYPANOSOMA
4 LEISHMANIA
5 FILARIA
6 JAPANESE ENCEPHALITIS
Fast Facts Issues
• No DW manufactures develop new vaccines.
• Most DW manufactures are biogeneric players.
• DC manufactures follow MNCs.
• Our Mission is to change that mindset.
NEGLECTED DISEASES
GLOBAL DISEASES

Emerging Market Value Proposition
Bharat Biotech Strategy
Population
Birth Cohort
Health Care Budgets
Increasing
Health Care Budgets
Decreasing
Our growth path for
future is here
Emerging
6 Billion
125 Million
Low Value
High Volume
Products R&D Pipeline Projects RecognitionFast Facts Issues
Developed
0.75 Billion
7.5 Million
High Value
Low Volume

Products

JE Launch
The Union Health & Family Welfare Minister, Shri Ghulam Nabi Azad launching
Japanese Encephalitis vaccine on 04th October, 2013 in New Delhi
Products R&D Pipeline Projects RecognitionIssuesFast Facts
Purified, Inactivated Japanese Encephalitis Vaccine
1st indigenously developed

TCV Launch
Vi Capsular Polysaccharide Tetanus Toxoid Conjugate Vaccine
World’s 1st Clinically Proven Typhoid Conjugate Vaccine
Dr. Christian Loucq - International Vaccine Institute Director-General launching
Typhoid Conjugate Vaccine in Hyderabad on 26th August, 2013

Product Launches
Dr. A.P.J. Abdul Kalam
Former President of India, launching
Dr. John Robbins
Father of Polysaccharide Vaccine
National Institute of Health, USA, launching
Dr. Julie Gerberding
Former Director of the U.S. Centers for
Disease Control, launching
IssuesFast Facts

Vaccines
Wide Product Portfolio
S. No. Vaccine Brand
1 DPT+ Hep B + Hib Comvac 5 ®
2 DPT+ Hep B Comvac 4-Hb ®
3 DPT; TT, DT Comvac 3 ™
4 Hep B Revac B+ ®
5 Hep B Revac B mcf ®
6 Hib BioHib ™
7 Typhoid Typbar ®
8 Typhoid Typbar TCV ™
9 OPV Trivalent BIOPOLIO ®
10 OPV Monovalent Type-1 BIOPOLIO M1 ™
11 OPV Monovalent Type-3 BIOPOLIO M3 ™
12 OPV Bivalent BIOPOLIO B1/3 ™
13 JE Jenvac ®
1 Typhoid Typbar ®
3 Rabies INDIRAB ®
4 Influenza HN VAC ™
5 JE Jenvac ®
1 Typhoid Typbar ®
3 Influenza HN VAC ™
4 JE Jenvac ®
Children & Adult
Traveler
Children

Bio-therapeutics
Wide Product Portfolio
S. No. Bio-therapeutic Brand
1 Probiotic Yeast BIOGIT™
2
Recombinant Human Epidermal
Growth Factor
REGEN-D ®
3
Recombinant Human Epidermal
Growth Factor, Silver Sulfadiazine &
Chlorexidine Gluconate Cream
SLVRGEN ®
4 Zinc with ORS ZELECT ®

Product Distribution
More than 2 Billion doses delivered

More than 2 Billion doses delivered
Korea
Nepal
Philippines
Brazil
(ANVISA)
Sri Lanka
Saudi
Arabia
Colombia
(INVIMA)
Ghana
KenyaCongo
Turkey
Kazakhstan
Uganda
Syria
Malawi
Ukraine
Belarus
Ivory Coast
Accreditation
Pakistan
Myanmar

R&D Pipeline

Pipeline Products
1st Time in the world Typhoid Conjugate Vaccine
S. No. Vaccines Product
Development
Preclinical
Testing Phase I Phase II Phase III Commercial
License
1 Chikungunya 2017
2 Malaria PvRII 2017
3 Staph Aureus MRSA 2018
4 Human Papilloma Virus 2018
5 Acellular Pertussis 2016
6 Tetanus (Meat Free) 2016
7 S. Paratyphi 2018
8 NTS Conjugates 2018
9 Sabin IPV 2018
Therapeutics Product
Development
Preclinical
Testing Phase I Phase II Phase III Commercial
License
1 THR-100 2015
2 Lysostaphin Topical 2015
3 Lysostaphin IV 2017
4 r Human Serum Albumin 2014
IssuesFast Facts

Projects

Recognition

Recognition of Achievements
Young Enterprising Company
VOA awards 2013
most promising vaccines for paediatric
16th March, 2013
Pharma Bio World Award
Business Leader of the Year
Biotechnology 2011
Best R&D Company of the year 2010
by Pharmaceutical Leadership Summit
2010 Mumbai
National Technology
Award Govt of India 2006
Business Innovation Marico Foundation
& Business World 2006

Recognition of Achievements
Young Enterprising Company
JRD TATA Best Entrepreneur award FICCI Award Excellence in Science
Best Performance in Technology
Marico Foundation Innovation Award
TDB National award DBT-award for Product & Process

“Our mission is to address the health care needs of emerging markets,
drive innovation, be a front runner in research and development of
new vaccines and bio-therapeutics”
Mission 7 Billion
Dr. Krishna M. Ella
Chairman & Managing Director

Thank You
Address
Bharat Biotech International Limited
Genome Valley, Shameerpet Mandal,
Ranga Reddy District - 500 078 Andhra Pradesh, India.
Tel.: +91 40 2348 0567
Fax: +91 40 2348 0560
info@bharatbiotech.com

Bharat Biotech Corporate Profile and Product Pipeline

Recommended

More Related Content

What's hot

What's hot (20)

Viewers also liked

Viewers also liked (20)

Similar to Bharat Biotech Corporate Profile and Product Pipeline

Similar to Bharat Biotech Corporate Profile and Product Pipeline (20)

Recently uploaded

Recently uploaded (20)

Bharat Biotech Corporate Profile and Product Pipeline